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The development of novel theranostic agents is an important step in the pathway 
towards personalised medicine, with the combination of diagnostic and therapeutic 
modalities into a single treatment agent naturally lending itself to the optimisation and 
personalisation of treatment. In pursuit of the goal of a molecular theranostic suitable for 
use as a PET radiotracer and a photosensitiser for PDT, a novel radiolabelled peptide- 
porphyrin conjugate targeting the α6β1-integrin has been developed. 69/71Ga and 68Ga 
labelling of an azide-functionalised porphyrin has been carried out in excellent yields, 
with subsequent bioconjugation to an alkyne-functionalised peptide demonstrated. α6β1-
integrin expression of two cell lines has been evaluated by flow cytometry, and 
therapeutic potential of the conjugate demonstrated. Evaluation of the phototoxicity of 
the porphyrin-peptide theranostic conjugate in comparison to an untargeted control 
porphyrin in vitro, demonstrated significantly enhanced activity for a cell line with higher 
α6β1-integrin expression when compared with a cell line exhibiting lower α6β1-integrin 
expression. 
Introduction 
The goal of developing personalised medicine is an emerging trend within both clinical and scientific areas of research, and is of 
particular interest in the treatment of neoplastic conditions. Tumour heterogeneity in patient populations can be vast and can lead 
to significant differences in patient outcomes when using standardised treatments. It is unsurprising, that the development of novel 
theranostics is also a growing trend in research, with the combination of diagnostic and therapeutic modalities into a single agent 
naturally lending itself to the optimisation and personalisation of treatment. While the majority of work in the area of theranostics 
utilises nanoparticles either for conjugation, or encapsulation, of two or more distinct treatment and imaging agents (see Xie et al 
for a comprehensive review1), progress has also been seen in the area of molecular theranostics, allowing the combination of 
therapeutic and diagnostic abilities without the need for synthesis of complex nanostructures. 
Porphyrins naturally lend themselves to the area of molecular theranostics, with many examples in the literature of their separate 
use in both therapeutic and diagnostic capacities. The therapeutic abilities of porphyrins are undisputed; their favourable 
photophysical properties, and relative ease of both synthesis and functionalization, has led to their dominance in the field of 
photodynamic therapy; with their potent and selective cytotoxic action on tumour tissue being extensively documented2, 3. In 
addition, while both endogenous and exogenous free-base porphyrins have cemented their position as field-leaders in the area of 
fluorescent imaging4, the utility of porphyrins as chelators for a host of metals suitable for imaging applications allows the use of 
these metallated porphyrins as positron emission tomography (PET), single-photon emission computed tomography (SPECT) or 
magnetic resonance imaging (MRI) agents.5  
PET imaging is of particular interest for theranostic applications, offering functional imaging for the detection of metabolic 
changes in neoplastic tissues, rather than the mainly structural imaging offered by MRI. This provides good quality images while 
minimising the need for invasive biopsies to determine tumour malignancy. While the clinically approved 18F radiolabelled 2-
fluorodeoxyglucose (FDG) is currently considered to be the “gold standard” of PET-imaging agents, uptake of FDG is an 
untargeted process, relying solely on the increased metabolism of the neoplastic tissue to promote tumour localisation. 
Development of alternative radiotracers which target tumour-associated receptors allows characterisation of cell biomarker 
expression and can give an indication of prognosis as well as allowing personalised planning of treatment. In particular, the 
radiolabelling of therapeutic agents such as photosensitisers also provides valuable information regarding the uptake and 
localisation of the molecule, as well as providing an indication of likely responses to PDT treatment.  
The vast majority of porphyrin radiolabelling strategies in the literature have utilised the porphyrin as a chelating agent for 
radioisotopes such as Cu-646-8, Ga-689-11, and Nd-14012 (see Waghorn et al. for a  comprehensive review of radiolabelled 
porphyrins13). However, chelation of paramagnetic isotopes quenches the therapeutic action of the porphyrin, requiring use of the 
unmetallated porphyrin as the treatment agent. This is a major limitation in utilising radioisotopes such as 64Cu, since it 
necessitates the administration of therapeutic and diagnostic agents in separate doses, with an appropriate delay between these 
doses to allow clearance of the radiolabelled species. In addition, it has previously been demonstrated that alteration in tumour 
uptake can occur upon metallation of porphyrin photosensitisers14, 15, limiting the usefulness of any imaging data generated in this 
way. As gallium (III) is diamagnetic, chelation of 68Ga by the porphyrin photosensitiser can be utilised to produce a theranostic 
which maintains functionality as both a PDT and a PET agent.    
Despite the potential utility of 68Ga porphyrins as diagnostic agents, to date there have been few published examples of the 
development of these metallo-porphyrins as radiotracers for PET. 68Ga radiolabelling of both exogenous11, and targeted9 and 
untargeted10 endogenous porphyrins has been carried out in radiochemical yields (RCY) of between 22-73%, with the utility of 
these radiotracers as both PET10, 11 and fluorescent9 imaging agents demonstrated. However, to date no examples of gallium-
labelled porphyrins have undergone biological evaluation as therapeutic agents, and no examples of 68Ga radiolabelling of 
exogenous, water-soluble porphyrins have been published.  
It was therefore envisaged that the development of novel targeted theranostic agents could be achieved through the combination of 
the demonstrated radiolabelling potential of porphyrins with our current interest in the mild bio-orthogonal conjugation of 
porphyrin photosensitisers to targeting moieties16-18 through use of the Copper-Catalysed Azide-Alkyne Cycloaddition (CuAAC) 
reaction. This reaction is mild and generally high yielding19, 20 and has been shown to be highly compatible with both porphyrin 
bioconjugation and radiochemistry, being largely insensitive to steric hindrance and operating well in aqueous conditions without 
the need for high temperatures or long reaction times.  
Results and discussion 
Evaluation of cell receptor expression 
Conjugation of a targeting peptide to the radiolabelled porphyrin was selected as this strategy is highly compatible with short-lived 
radioisotopes; the small size of peptides allows accumulation in target tissue in a short time period, and rapid clearance from the 
bloodstream. Imaging of the cell-surface integrin receptors utilising PET has previously been demonstrated utilising both 68Ga- 
and 18F-21, 22 labelled peptides and has been shown to be particularly effective in the determination of both metastasis and 
angiogenesis associated with tumours. 
The dodecapeptide TWYKIAFQRNRK was first characterised in 1996 by Nakahara et al. 23, and exhibits a good affinity for the 
α6β1-integrin24.  While this integrin is involved in cellular migration and adhesion in normal tissue, it is also upregulated in 
multiple cancers, including breast carcinomas and glioblastomas, in which it is associated with the facilitation of tumorigenesis 
and promotion of metastasis.25 Despite this, the use of this peptide in imaging applications is controversial, as its binding has in 
some cases demonstrated stimulation of the invadopodial activity of the integrin.26 However, use in targeted theranostic conjugates 
would allow treatment immediately following imaging, limiting the deleterious effects of the integrin signalling activation.  
In order to confirm retention of the α6β1-integrin targeting ability of the peptide following synthesis of the porphyrin-peptide 
theranostic, two cell lines exhibiting a differential in α6β1-integrin expression were required. However, due to the essential roles 
played by the α6β1-integrin in normal cells some basal expression is always present, and therefore knock out of integrin expression 
in order to generate a “negative” control cell line does not produce an accurate model of the in vivo environment.. For this reason, 
we evaluated two cell lines to ascertain the differential in their natural integrin expression via relative fluorescent intensity. As 
illustrated in panel A of figure 1, a large dynamic range of expression was observed, with the cell lines displaying natural integrin 
receptor quantities over two orders of magnitude.  
In order to quantify how these levels of expression could be correlated to the number of receptors, fluorescently calibrated beads 
were used in order to provide quantification of the number of receptors on the cell surface (panel B of Figure 1). In particular, the 
U87 cell line was shown to have extremely low levels of integrin expression, while in contrast the HeLa cell line was found to be 
integrin high expressing.  
Figure 1:  Quantification of integrin expression on cell surface.  Panel A depicts relative fluorescence intensity of cells measured by FACS; the grey histogram depicts 
the negative control which is similar between the different cells.  Panel B depicts the quantification of the receptor number per cell accomplished with calibrated 
fluorescence beads. The error bars depict standard deviation.  
Synthesis of 69/71Ga porphyrins 
Two water-soluble cationic porphyrins bearing azide functionalities were selected for synthesis in this work. These porphyrins 
have previously been shown to exhibit potent cytotoxic action even when metallated with zinc,18 and also undergo click reactions 
rapidly without the need for reaction intensification17, important for the rapid click conjugation of a thermally-sensitive peptide 
following radiolabelling. Synthesis of the porphyrins was carried out according to a previously described method17, with the free 
base porphyrins obtained in excellent overall yield. Metallation with “cold” 69/71Ga was then carried out to produce the gallium 
complex for use as HPLC standard and for use in biological evaluation (figure 2).  
In previously described literature synthesis of gallium porphyrins10, microwave irradiation has been utilised in order to facilitate 
metal chelation, showing considerably improved rates of reaction and yields in comparison to conventional heating. Microwave 
irradiation also allows for solvents to be heated under pressure above their boiling points, allowing the use of water as a solvent at 
temperatures above 100°C. Initially, microwave heating of porphyrin 1 to 160 °C in aqueous conditions with gallium (III) chloride 
was shown to be extremely effective, with complete metallation observed by TLC after 1.5 minutes. However, formation of a 
second metallated porphyrin by-product was also observed as a result of thermal degradation of the azide functionality. 
Figure 2:  General metallation methodology for gallium insertion into the porphyrins. 
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Optimisation of reaction time and temperature demonstrated complete cessation of thermal azide degradation below 100°C, 
however metallation below this temperature was also slow, taking in excess of 40 minutes to achieve complete conversion to 
product 3. For this reason, a reaction temperature of 110°C was selected; while some degradation was observed at this temperature 
with reaction times longer than 15 minutes, TLC monitoring of the reaction displayed complete conversion of the starting material 
to 3 after 7 minutes heating, with no appreciable formation of by-products. These optimised reaction conditions were also utilised 
to produce 4; in both cases the desired product was obtained in near-quantitative yield following the described workup, with no 
further purification required.  
Click conjugation of 69/71Ga porphyrin to peptide 
Following the successful metallation of porphyrins 3 and 4, click conjugation to the alkyne dodecapeptide was then attempted 
(figure 3). Click conjugation to the porphyrin prior to gallium insertion was not attempted as the high temperatures required for 
metallation are incompatible with the peptide. In addition, click conjugation prior to metallation would necessitate the inclusion of 
a protective metallation step to protect the porphyrin central cavity from copper insertion during the click reaction. Reaction of 
both porphyrins 3 and 4 with the peptide was attempted in an aqueous system at room temperature, with the reaction monitored by 
HPLC. Despite the similarity between the two structures, reaction rates were markedly different, with porphyrin 3 demonstrating 
no appreciable formation of the bioconjugate after 3 hours.  
This poor reactivity was attributed to the high steric hindrance of the system, with the addition of the linker chain in porphyrin 4 
significantly increasing the rate of reaction. Product formation was evident after 20 minutes reaction time, with no further reaction 
observed after 1 hour. Interestingly, this reaction rate is considerably slower than that observed in previous examples of the click 
conjugation of this porphyrin17, with the longer reaction time attributed both to the increased steric bulk of the peptide..  
A one-pot, two-step metallation and click methodology was also investigated, and while neutralisation of the solution was required 
before addition of the peptide, no other workup was required between steps and no effect on yield or reaction time was observed. 
Following reaction completion, the product was purified on a Sephadex G15 column to remove unreacted starting materials and 
reagents, and the product lyophilised overnight to produce the desired product as characterised by HPLC and MS.  
Figure 3:  Click conjugation of Ga-porphyrin 4 to integrin-targeting dodecapeptide TWYKIAFQRNRK. The reaction was conducted utilising copper (II) sulfate and 
sodium ascorbate to generate the Cu (I) catalyst in situ, with addition of THPTA as a water soluble Cu (I) ligand and aminoguanidine as a sacrificial agent to protect 
reactive residues from side reaction with oxidised sodium ascorbate species.27   
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Evaluation of phototoxicity 
Confirmation of the potential of the targeted theranostic to differentiate between high and low integrin expressing cells was carried 
out through evaluation of the phototoxicity of conjugate 5 in both a highly integrin expressing cell line (HeLa) and a cell line 
displaying minimal integrin expression (U87). In order to confirm that the selectivity of this conjugate was as a result of the 
peptide targeting, synthesis of a control, untargeted porphyrin 6 was carried out through the end-capping of porphyrin 4 with 
propargyl alcohol to prevent potential singlet oxygen quenching by the azide functionality (figure 4). The phototoxic action of this 
control conjugate was then assessed in the same cell lines.  
Figure 4:  Structures of peptide-targeted conjugate 5 and the control, untargeted porphyrin 6. 
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Irradiation of both conjugates 5 and 6 was carried out using a light system filtered to remove light below 515nm, and the results 
compared to a non-irradiated control. The irradiating light chosen aligns well with the position of the two Q-bands in the gallium 
porphyrin spectra allowing good light absorption, however excludes absorption at the porphyrin Soret band, allowing greater 
applicability of the results to an in vivo clinical setting. Under these conditions it can be seen that conjugate 5 exhibited excellent 
ability to eradicate the highly integrin expressing HeLa cell line (ca. 80% kill), while at the same concentration showing 
considerably lower cell killing in the U87 control cell line (Figure 5). Minimal dark toxicity was observed for this conjugate, with 
both cell lines displaying >75% cell survival at all concentrations in the absence of irradiation. In contrast, at the same 
concentrations the control porphyrin 6 displayed minimal cytotoxicity in both cell lines, with less than 20% cell kill observed in 
both irradiated and non-irradiated conditions for both cell lines. The limited cytotoxicity of 6 was attributed to the lack of cellular 
uptake; while the cellular targeting and subsequent internalisation of the α6β1-integrin allows uptake of conjugate 5 into target 
cells, no uptake of the untargeted control 6 was detected by fluorescence microscopy. 
Figure 5:  Graph of cytoxicity assay. Assay was carried out on both positive (HeLa) and negative (U87) cell lines, with results displayed for conjugate 5 and control 
compound 6 following irradiation (IRR) and non-irradiated (NIR). 
Synthesis of 68Ga radiolabelled conjugate 
Following the successful synthesis of the 69/71Ga conjugate 5, development of a methodology utilising “hot” 68Ga was carried out. 
Radiolabelling of porphyrin 2 was carried out under microwave irradiation at 110 °C due to the thermal instability of the azide 
functionality above this temperature. The radiolabelling was found to proceed well in 0.6M HCl at this temperature, removing the 
need to alter the pH or buffer the solution of 68Ga prior to chelation. Increasing reaction time was not found to significantly 
improve radiolabelling, with reaction times of longer than five minutes showing increased formation of unlabelled by-products 
with little improvement in RCY, however reaction optimisation demonstrated improving radiochemical yields (RCY) with 
increasing quantities of porphyrin 2, with >95% RCY obtained with addition of 20 mg of the chelating porphyrin (figure 6).  
Following radiolabelling, the remaining unlabelled porphyrin was metallated with 69/71Ga to create a carrier-added radiotracer. 
While the generation of such carrier-added systems is generally not optimal for PET imaging, it was preferred in this instance due 
to the large difference in the quantity of administered theranostic required for PET and PDT; while PET imaging is sensitive to 
low nanomolar quantities of radiotracers, PDT requires high nanomolar to micromolar quantities of the photosensitiser. 
0.0
20.0
40.0
60.0
80.0
100.0
120.0
HeLa U87
Ce
ll 
su
rv
iv
al
 (%
)
Cell line
5-IRR
5-NIR
6-IRR
6-NIR
Administration of the carrier-added radiotracer in this way allows treatment following imaging without the need for administration 
of a second dose of the theranostic.  
69/71Ga metallation was carried out under microwave heating as for the synthesis of porphyrin 4. HPLC analysis showed that 
addition of the GaCl3 directly to the solution of radiolabelled porphyrin 4-Ga68 gave poor yields, with the radiochromatogram 
showing formation of significant quantities of the thermal degradation by-product. Dilution of the mixture with 200 μl of water 
before addition of gallium (III) chloride improved solubilisation of the porphyrin in the solution, and produced essentially 
quantitative complexation of all unlabelled porphyrin after 3 minutes of heating with less than 10% of the thermal degradation 
product observed. Heating beyond this time also increased degradation of the azide and did not improve yields.  
Figure 6:  HPLC analysis of radiolabelling results. A: radiochromatograpm of  gallium-radiolabelled porphyrin 4-Ga68 overlaid with UV-chromatogram of cold standard 
4. B: UV-chromatogram of free-base porphyrin 2 C: radiochromatogram of gallium-radiolabelled porphyrin 4-Ga68 (carrier added). D: radiochromatogram of click
reaction between dodecapeptide and porphyrin 4-Ga68 to produce conjugate 5-Ga68. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Click conjugation of the peptide to the radiolabelled porphyrin was then attempted utilising the one-pot methodology previously 
developed on porphyrin 4. In this case, the dodecapeptide and the Cu (I) catalyst system were added to the radiolabelled porphyrin 
solution following neutralisation with sodium hydrogen carbonate, and the mixture stirred at room temperature. RadioHPLC 
analysis was carried to ascertain reaction completion, with the formation of the conjugate confirmed with a new peak at 8:40 
minutes. A RCY of 19% was obtained after 20 minutes, with no formation of radiolabelled by-products observed. Although 
residual precursor porphyrin 4-Ga68 was also evident, the large difference in Rf values observed between the porphyrin 4-Ga68 
and conjugate 5-Ga68 would allow for the development of a prep-HPLC methodology to isolate the pure conjugate. Alternatively, 
purification by Sephadex G15 as demonstrated on 69/71Ga conjugate 5 would allow for facile isolation of the pure theranostic 
conjugate without the need for HPLC purification.  
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Conclusions 
In conclusion, we have demonstrated the gallium complexation and peptide bioconjugation of an azide-functionalised porphyrin to 
produce a novel targeted theranostic conjugate. α6β1-integrin expression of three cell lines was evaluated by flow cytometry, with 
the FITC-labelled TWYKIAFQRNRK peptide showing good localisation in an α6β1-integrin overexpressing cell line. Subsequent 
evaluation of the therapeutic effects of the porphyrin-peptide theranostic conjugate in comparison to an untargeted control in vitro 
demonstrated good selectivity for a highly integrin expressing cell line over the control cell line, with little dark toxicity observed 
in both cell lines. 
Experimental 
Materials and methods 
1H and 13C NMR spectra were recorded on JEOL Eclipse 400 and JEOL Lambda 400 spectrometers (operating at 400 MHz for 1H 
and 100 MHz for 13C). Chemical shifts (δ) are reported in parts per million (ppm), referenced to DMSO. Coupling constants (J) are 
recorded in Hz and significant multiplicities described by singlet (s), doublet (d), multiplet (m). MALDI mass spectra were 
performed by the EPSRC National Mass Spectrometry Facilities, Swansea, UK. UV−visible spectra were recorded on a Varian 
Cary spectrophotometer. Chemical reagents and solvents were purchased from Sigma-Aldrich and Alfa Aesar, and were used as 
received unless otherwise stated. Peptide was purchased from PeptideSynthetics. Gel filtrations were performed on Sephadex® G-
15 medium (GE Healthcare, UK), using deionised water as the eluent. 68Ga was produced on a 68Ge/68Ga iThemba LABs gallium 
generator, and eluted with 3 ml 0.6M HCl. Activity was measured using a Capintec Inc CRC-55t dose calibrator. Microwave 
reactions were carried out in a CEM Discover Benchmate microwave reactor controlled using Synergy software. In all cases, 
maximum stirring, maximum pressure of 200 bar and 2 minute maximum heating step were used. Reaction temperatures were 
monitored using an external IR probe and carried out in a 10ml sealed reaction vessel. Irradiation of cells during phototoxicity 
assays was carried out using an Oriel lamp system with a Schott 06515 Long Pass Optical Filter, allowing irradiation with 95-98% 
of light above 515 nm. RP-HPLC analyses were performed on a Agilent 1100 with a Lablogic NaI gamma detector. The 
separations were performed on a Gemini C1 8 column, 5µ, 150 x 4.6 mm, 110 Å (Phenomenex, UK) at a flow rate of 1 mL/min, 
with a mobile phase consisting of 0.1% TFA in water (solvent A) and 0.1% TFA in acetonitrile (solvent B). Gradient: 0.0–12.0 
min 0-40% solvent B, 10.2–13.9 min 95% solvent B, 13.9–14.0 min at 95-5% solvent B, 14.0–16.0 min 5% solvent B. 5-(4-
azidophenyl)-10,15,20-tris(4-methylpyridiniumyl)porphyrinato trichloride, and 5-[4-2-(2-(2-azidoethoxy)ethoxy) 
ethanaminocarbonyl]phenyl]-10,15,20-tris(1-methyl-pyridinium-4-yl)porphyrin trichloride, were synthesised following procedures 
reported in the literature.18  
Synthetic procedures 
General procedure for synthesis of gallium porphyrins: 
To a microwave tube was added the porphyrin (0.012 mmol) and water (5 ml). Gallium (III) chloride (10 mg, 0.06 mmol) was 
added and the mixture heated to 110°C (100W, MW) for 5 minutes. The mixture was neutralised with saturated sodium 
bicarbonate, and ammonium hexafluorophosphate added. The precipitated product was collected by filtration and redissolved in 
acetone. Tetrabutylammonium chloride was added and the precipitated product was collected by filtration. The product was 
precipitated from diethyl ether over methanol to yield the product as a red-purple solid. 
General click reaction conditions: 
To a stirred solution of gallium porphyrin (2.0 μmol) in water (1 ml) was added THPTA (174 μg, 0.4 μmol), aminoguanidine 
bicarbonate (54 μg, 0.4 μmol) and copper (II) sulfate pentahydrate (50 μg, 0.2 μmol) and sodium ascorbate (80 μg, 0.4 μmol) in 
water (0.2 ml). The dodecapeptide (2 mg, 1.7 μmol) in water (2 ml) was added and the mixture stirred at rt for 1 hour. The crude 
was purified on a column of Sephadex G-15, and lyophilised to remove water, to isolate the product as a pale green powder.  
Cytotoxicity assays: 
The Gallium-porphyrin control dye was formulated in 5%DMSO/MEM and further diluted in MEM medium (+2mM L-glutamine 
but no FCS) to give a range of concentrations (between 1x10-4 to 7.5 x10-6M). The Gallium-porphyrin-peptide dye was formulated 
in 5% DMSO/H2O and further diluted as above to give a range of concentrations (between 3x10-5 to 3.75 x10-6M). The two cell 
types (HeLa and U87) were adjusted to a concentration of 1x106 cells /ml, added to the dilutions and incubated in the dark for an 
hour at 37°C and 5% CO2 after which they were washed in a 3x excess of medium to eliminate any unbound dye. The pellets of 
cells and porphyrin were re-suspended in 1ml medium and 4x100µl of each concentration put in two 96 wells plates. One plate 
was irradiated with light (5.0 J/cm2) while the other served as dark toxicity control. After irradiation, 5 µl of Fetal Bovine Serum 
was added to each well and the plates were returned to the incubator overnight. After 18 to 24 hours, an MTT cell viability assay 
was performed and the results expressed as % of cell viability versus porphyrin concentration. 
 
Flow Cytometry 
Expression of α6-integrin on the cells, U87MG and Hela (purchased from ECAC and maintained in DMEM as described above) 
was assessed and quantified using flow cytometry. Cells were harvested using PBS/EDTA (12mM EDTA) and incubated with 
Phycoerythin (PE) conjugated antibodies for α6-integrin (BD Biosciences) in DMEM supplemented with1% BSA for 1 hour with 
gentle rocking at 4°C. Following labelling, cells were washed 3 times with DMEM containing 1% BSA and fixed with 1% 
paraformaldehyde for 15 min at 4°C. After three washes with PBS supplemented with 1% BSA, fluorescence was quantified using 
BD FACSCalibur. Receptor expression was quantified using calibration to fluorescence intensity using BD QuantiBRITE PE bead 
kit. A sample of PE labelled beads was run immediately following the experimental samples, using the same instrument settings. 
According to the manufacturer specification a standard curve for the fluorescence intensity and number of fluorophores per bead 
was constructed and used to calculate the number of receptors per cell assuming a one to one binding ratio (one PE-antibody per 
cellular integrin). 
 
Radiochemistry 
Labelling with gallium-68: To a microwave tube containing porphyrin 1 (20 mg, mmol) or 2 (20 mg, mmol) was added a solution 
of 0.6 M HCl (200 μl) containing the Ga-68 activity (10 MBq), and the solution diluted with 300 μl water. The mixture was heated 
to 110 °C for the required length of time (100 W, MW), and labelling yields were determined by HPLC. 
 
Metallation with cold carrier gallium: 
To a microwave tube containing the labelled porphyrin (10 MBq) in solution was added gallium (III) chloride (2 mg, 0.0012 
mmol). The mixture was heated to 110 °C for the required length of time (100 W, MW), and gallium incorporation was 
determined by TLC (1:1:8 sat KNO3 solution:water:acetonitrile).  
 
Conjugation to peptide: 
To a stirred solution of gallium porphyrin (1 MBq) in water (1 ml) was added THPTA (174 μg, 0.4 μmol), aminoguanidine 
bicarbonate (54 μg, 0.4 μmol) and copper (II) sulfate pentahydrate (50 μg, 0.2 μmol) and sodium ascorbate (80 μg, 0.4 μmol) in 
water (0.2 ml). The dodecapeptide (2 mg, 1.7 μmol) in water (2 ml) was added and the mixture stirred at RT for 20 mins. 
Radiochemical yields were determined by HPLC. 
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